越南嘉莱省双氢青蒿素哌喹治疗无并发症恶性疟的疗效监测
2022年3月至2023年12月在越南嘉莱省开展开放标签单臂试验,120例无并发症恶性疟患者接受双氢青蒿素哌喹(Pyramax®)三日疗法加单剂伯氨喹。第42天PCR校正的充分临床和寄生虫学应答率为92.5%(95%CI:85.5-96.2;98/106),但复燃患者第7天哌喹血药浓度较低,提示药物暴露不足可能与治疗失败相关。
要点
- 第42天PCR校正充分临床和寄生虫学应答率为92.5%(95%CI:85.5-96.2;98/106)。
- 50.4%(60/119)患者治疗72小时显微镜仍检出疟原虫,提示部分青蒿素耐药。
- 复燃患者第7天哌喹血药浓度较低(P=0.065),提示暴露不足可能与失败相关。
核心结论
- Pyramax®在越南嘉莱省治疗无并发症恶性疟仍有效,但复燃患者哌喹暴露较低值得关注。
研究设计与样本
- 开放标签单臂试验,纳入120例成人和儿童恶性疟患者,2022年3月至2023年12月在越南嘉莱省开展。
- 患者接受Pyramax®每日一次连用3天及单剂伯氨喹,直接观察治疗。
- 用液相色谱-质谱法测定患者第7天血液哌喹浓度以评估药物暴露。
主要发现
- 第42天PCR校正的充分临床和寄生虫学应答率为92.5%(95%CI:85.5-96.2;98/106)。
- 中位原虫清除时间和退热时间分别为84小时(范围24-132)和36小时(范围12-108)。
- 中位原虫清除半衰期为7.4小时(IQR 6.3-8.4),50.4%(60/119)患者在治疗72小时显微镜检出原虫。
- 8例复燃患者第7天哌喹浓度(均值39.6 ng/mL,中位33.3 ng/mL,范围12.4-90.5)低于第42天无疟的95例患者(中位47.6 ng/mL,范围10.6-123.0),P=0.065。
关键数值与推荐
- 第42天PCR校正充分临床和寄生虫学应答率92.5%(95%CI:85.5-96.2;98/106)。
- 治疗72小时显微镜检出原虫者占50.4%(60/119),提示部分青蒿素耐药。
- 复燃患者与无疟患者第7天哌喹浓度比较P=0.065。
临床怎么用
- 在部分青蒿素耐药地区使用Pyramax®时需监测疗效,关注复燃及药物暴露不足的可能。
局限性
- 单臂设计、样本量有限,哌喹浓度与复燃的关联P=0.065未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We assessed the therapeutic efficacy of pyronaridine-artesunate (Pyramax®) for the treatment of uncomplicated Plasmodium falciparum malaria in Gia Lai province, Central Vietnam where parasites are partially resistant to artemisinins. METHODS: In an open-label, single-arm trial, Pyramax® was administered to 120 patients (adults and children) infected with P. falciparum residing in Gia Lai province from March 2022 to December 2023. Patients received Pyramax® once daily for 3 days and single-dose primaquine under direct observation therapy. Patients' Day 7 blood pyronaridine concentrations were measured by liquid chromatography-mass spectrometry to determine drug exposure. RESULTS: After Pyramax® treatment, the proportion of patients with PCR-adjusted adequate clinical and parasitological response at Day 42 was 92.5% (95% CI: 85.5-96.2; 98/106). The median parasite and fever clearance times were 84 h (range: 24-132) and 36 h (range: 12-108), respectively. The median (IQR) parasite clearance half-life was 7.4 h (6.3-8.4), with 50.4% (60/119) of patients had parasites detected by microscopy at 72 h after commencing treatment, suggestive of partial artemisinin resistance. The eight patients who experienced malaria recrudescence had lower (P = 0.065) blood pyronaridine concentrations (mean 39.6 ng/mL, median 33.3 ng/mL, range: 12.4-90.5) compared to the 95 patients who were malaria-free by Day 42 (median 47.6 ng/mL, range: 10.6-123.0). CONCLUSIONS: Although Pyramax® remains efficacious in treating P. falciparum, the lower pyronaridine concentrations in patients who had recrudescent malaria are worrisome and suggest that reduced pyronaridine exposure may be responsible for the Pyramax® treatment failures.
引用
- Van Thanh N, Quang HH, San NN, et al. Therapeutic efficacy monitoring of pyronaridine-artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023. J Antimicrob Chemother. 2025. PMID: 40796211. doi:10.1093/jac/dkaf234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。